Related Experiment Video

Updated: Aug 22, 2025

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

8.4K

FADD as a key molecular player in cancer progression

Ying Liu1,2, Xiaoge Li3, Xuehao Zhou3

  • 1Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, Qingdao Medical College, Qingdao University, 266021, Qingdao, China. yingliu@qdu.edu.cn.

Molecular Medicine (Cambridge, Mass.)
|November 8, 2022
PubMed

Insights

Fas-associated protein with death domain (FADD) is crucial in cancer, influencing non-apoptotic processes. Understanding FADD

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cancer is a major global health issue with complex, often unknown, pathogenesis.
  • Fas-associated protein with death domain (FADD) is an adaptor protein initially linked to apoptosis.
  • Emerging evidence highlights FADD's significant roles in non-apoptotic cellular functions like proliferation, autophagy, and necroptosis.

Purpose of the Study:

  • To review the structure, functions, and regulatory mechanisms of FADD.
  • To focus on the role of FADD dysregulation in cancer progression.
  • To discuss the clinical implications of FADD as a potential biomarker and therapeutic target in cancer.

Main Methods:

  • Literature review of recent findings on FADD.
  • Synthesis of information on FADD's structure, function, and regulation.
  • Analysis of FADD's involvement in various cancer types.

Main Results:

  • FADD expression and activity are regulated by complex networks including DNA methylation, non-coding RNA, and post-translational modifications.
  • FADD dysregulation is strongly associated with the pathogenesis of multiple cancers.
  • The precise mechanisms of FADD dysregulation in cancer progression require further elucidation.

Conclusions:

  • FADD plays a critical role in cancer pathogenesis beyond its known apoptotic functions.
  • Further research into FADD's regulatory mechanisms and cancer-specific roles is warranted.
  • FADD holds promise as a potential biomarker and therapeutic target for cancer treatment.
Keywords:
BiomarkerDrug resistanceFADDInflammationTherapeutic target

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

4.6K
Experimental Generation of Carcinoma-Associated Fibroblasts CAFs from Human Mammary Fibroblasts15:43

Experimental Generation of Carcinoma-Associated Fibroblasts CAFs from Human Mammary Fibroblasts

Published on: October 25, 2011

23.5K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.5K